MRP3、MRP4肿瘤相关研究进展

doi:10.12092/j.issn.1009-2501.2019.03.015

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (3): 327-331.doi: 10.12092/j.issn.1009-2501.2019.03.015

MRP3、MRP4肿瘤相关研究进展

宗思豆，张红

南昌大学，临床药理研究所，南昌 330006，江西

收稿日期:2018-11-21 修回日期:2019-01-08 出版日期:2019-03-26 发布日期:2019-04-01
通讯作者: 张红，副教授，硕士生导师，研究方向：临床药理学相关研究。 Tel：0791-86360654 E-mail：zh2003nc@163.com
作者简介:宗思豆，女，硕士研究生，研究方向：临床药理学相关研究。 Tel：18166043031 E-mail：1097607817@qq.com
基金资助:
国家自然科学基金资助项目（81660622）

Research progress of MRP3 and MRP4 transporters in tumor

ZONG Sidou, ZHANG Hong

Institute of Clinical Pharmacology, Nanchang University, Nanchang 330006, Jiangxi, China

Received:2018-11-21 Revised:2019-01-08 Online:2019-03-26 Published:2019-04-01

摘要/Abstract

摘要：

肿瘤相关分子机制研究受到广泛关注并且在肿瘤的诊断和治疗中的扮演着越来越重要的角色。MRP家族是一种跨膜ATP结合盒(ABC)转运体，对肿瘤分子机制研究有着重要的贡献，MRP3和MRP4作为MRP家族成员，是近年来比较新型的肿瘤分子靶点，具有潜在的临床价值。故本文就MRP3和MRP4的结构以及在肿瘤诊断或治疗作用及相关机制调控做一综述，为未来肿瘤的研究提供新的思路。

关键词: MRP3, MRP4, 肿瘤, 调节机制

Abstract:

The study of tumor molecular mechanism has received extensive attention and plays an increasingly important role in the diagnosis and treatment of tumor. MRP family is a transmembrane ATP binding box (ABC) transporter which plays an important role in the study of tumor molecular mechanism. As members of MRP family, MRP3 and MRP4 are novel molecular targets of tumor in recent years and have potential clinical value. Therefore, the structure of MRP3 and MRP4, the role of MRP3 and MRP4 in the diagnosis or treatment and the relevant regulation mechanisms are reviewed in this article to provide new ideas for the future research of tumor.

Key words: MRP3, MRP4, tumor, regulatory mechanism

中图分类号:

宗思豆，张红. MRP3、MRP4肿瘤相关研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 327-331.

ZONG Sidou, ZHANG Hong. Research progress of MRP3 and MRP4 transporters in tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 327-331.

参考文献

［1］Cai C, Omwancha J, Hsieh CL, et al. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells［J］. Prostate Cancer Prostatic Dis, 2007, 10(1): 39-45.
［2］Zhao X, Guo Y, Yue W, et al. ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer［J］. Onco Targets Ther, 2014, 7: 343-351.
［3］蒲聪颖，李珊，张媛媛. 肿瘤耐药性产生的分子机制研究进展［J］. 四川生理科学杂志, 2015, 11(2): 89-93.
［4］Kruh GD, Belinsky MG, Gallo JM, et al. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice ［J］. Cancer Meta Rev, 2007, 26(1): 5-14.
［5］高玮，张辉. 多药耐药相关蛋白3的研究进展［J］. 国际肿瘤学杂志, 2009, 8(4): 248-250.
［6］Russel F, Koenderink J, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules［J］. Trend Pharmacol Sci, 2008, 29(4): 200-207.
［7］Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3［J］. Lab Inves, 2002, 82(2): 193-201.
［8］Sciarra A, Schmidt S, Pellegrinelli A, et al. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy ［J］. Liver Int, 2019, 39(1): 158-167.
［9］Cirqueira CS, Felipe-Silva AS, Wakamatsu A, et al. Immunohistochemical assessment of the expression of biliary transportation proteins MRP2 and MRP3 in hepatocellular carcinoma and in cholangiocarcinoma ［J］. Pathol Oncol Res, 2019, 39(1): 158-167.
［10］Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin ［J］. Int J Cancer, 2002, 98(4): 630-635.
［11］Rady M, Mostageer M, Rohde J, et al. Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients［J］. Oncol Rep, 2017, 38(1): 551-560.
［12］Hanada S, Maeshima A, Matsuno Y, et al. Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression［J］. J Pathol, 2008, 216(1): 75-82.
［13］Kuan CT, Wakiya K, Herndon JN, et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy ［J］. BMC Cancer, 2010, 10: 468.
［14］Cai C, Omwancha J, Hsieh CL, et al. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells［J］. Prostate Cancer Prostatic Dis, 2007, 10(1): 39-45.
［15］He Z, Hu B, Tang L, et al. The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells ［J］. J Cancer Res Ther, 2015, 11(1): 18-23.
［16］Tomonari T, Takeishi S, Taniguchi T, et al. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma ［J］. Oncotarget, 2016, 7(6): 7207-7215.
［17］Wang LH, Ni CW, Lin YZ, et al. Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro［J］. Tumour Biol, 2014, 35(2): 1157-1168.
［18］Kuan CT, Wakiya K, Herndon JN, et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy ［J］. BMC Cancer, 2010, 10: 468.
［19］Partanen L, Staaf J, Tanner M, et al. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer ［J］. Genes Chromosomes Cancer, 2012, 51(9): 832-840.
［20］Rasmuson A, Kock A, Fuskevog OM, et al. Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma［J］. PLoS One, 2012, 7(1): e29331.
［21］Kochel TJ, Reader JC, Ma X, et al. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer［J］. Oncotarget, 2017, 8(4): 6540-6554.
［22］Huynh T, Norris MD, Haber M, et al. ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma ［J］. Front Oncol, 2012, 2: 178.
［23］He Z, Hu B, Tang L, et al. The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells ［J］. J Cancer Res Ther, 2015, 11(1): 18-23.
［24］Yu Z, Zhang C, Chai R, et al. Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma［J］. PLoS One, 2014, 9(1): e85446.
［25］Lin S, Hoffmann K, Xiao Z, et al. MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma ［J］. Cancer Cell Int, 2013, 13: 3.
［26］Kobayashi M, Funayama R, Ohnuma S, et al. Wnt-β-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer［J］. Cancer Sci, 2016, 107(12): 1776-1784.
［27］Ceballos MP, Decandido G, Quiroga AD, et al. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines［J］. Toxicol Lett, 2018, 289: 63-74.
［28］Brderdorf S, Zang S, Schaletzki Y, et al. cAMP regulates expression of the cyclic nucleotide transporter MRP4 (ABCC4) through the EPAC pathway ［J］. Pharmaco Geno, 2014, 24(10): 522-526.
［29］Porro A, Haber M, Diolaiti D, et al. Direct and coordinate regulation of ATP-binding cassette transporter genes by myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells ［J］. J Biol Chem, 2010, 285(25): 19532-19543.

[1]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[2]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[3]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[4]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[5]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[6]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[7]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[8]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[9]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[10]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[11]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[12]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[13]	洪子强, 苟文曦, 崔百强, 白向豆, 金大成, 苟云久. m7G甲基转移酶METTL1在肿瘤中的作用[J]. 中国临床药理学与治疗学, 2023, 28(1): 93-100.
[14]	缪亚东, 李蹊, 王燕, 高坡, 周敏, 于浩. 抗肿瘤药物临床试验数据管理的一般考虑[J]. 中国临床药理学与治疗学, 2022, 27(9): 1055-1060.
[15]	王亚丽, 霍续磊, 陈峰, 李生兰, 郑晓红, 王灿, 李文斌. 硝呋莫司抗肿瘤作用的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 955-960.

MRP3、MRP4肿瘤相关研究进展

Research progress of MRP3 and MRP4 transporters in tumor

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价